Sysmex Inostics
Chevonne D. Eversley, PhD, FACMG, has a distinguished career in molecular diagnostics and genetics, currently serving as the Laboratory Director and Head of Laboratory at Sysmex Inostics. Prior roles include Lab Director for Molecular NIPS at 54 Gene, Technical Director, Co-Discipline Director, and Managing Technical Director at LabCorp, and Director of the Molecular Diagnostics Laboratory at Northwestern Reproductive Genetics Service Corporation. Eversley completed a Clinical Molecular Genetics Fellowship at the Icahn School of Medicine at Mount Sinai and earned a PhD in Genetics and Molecular Biology from the University of North Carolina at Chapel Hill.
This person is not in any offices
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.